Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Low-income Breast Cancer Patients Skipping Hormonal Therapy, Increasing Their Risks
Many low-income women are failing to take the hormonal therapy prescribed as part of their breast cancer treatment, possibly lowering their survival rates, according to a study led by a researcher in the Duke Comprehensive Cancer Center.

Media Examines U.S. Government's Steps To Lift HIV Travel Ban
The New York Daily News on Friday examined the federal government"s recent actions to remove HIV from the list of diseases that can bar foreign residents from entry into the U.S. According to the Daily News, "The current regulations took effect in 1987, at the height of the worldwide AIDS scare," but, "[n]ow, with the backing of the Obama administration, the ban could be lifted by the end of the year." Martin Cetron, director of the CDC"s Division of Global Migration and Quarantine, said, "We"re trying to end the stigma and the discriminatory practice for a disease that doesn"t warrant exclusion for coming into this country." MSNBC.com reports that "immigration critics say they"re leery of the proposal that could allow an average of 4,275 HIV-infected people into the country annually, with a lifetime medical cost of about $94 million for those admitted during the first year, according to CDC estimates published this month in the Federal Register" (Aleccia, 7/17). Through Aug. 17, CDC is seeking public comment on the proposed rule to remove HIV from the list of diseases that can bar entry into the U.S. (Miller, 7/17).
News of the day
Genetically Elevated Levels Of Lipoprotein Associated With Increased Risk Of Heart Attack
A genetic analysis of data from three studies suggests that genetically elevated levels of lipoprotein(a) are associated with an increased risk of heart attack, according to a study in the June 10 issue of JAMA.
Oncology

PharmaCom BioVet To File With FDA In Order To Perform Clinical Trials - Cancer Treatment For Canines

PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to announce that it is preparing a Form 21 CFR 511.1(b) for submission to the Federal Drug Administration (FDA). This initial form is one of several required if the Corporation decides to potentially run clinical trials on a histone deacetylase inhibitor for canines, which the Corporation is planning to develop. The histone deacetylase inhibitor is potentially for dogs suffering from an acute type of cancer, canine hemangiosarcoma. "We are pleased to announce this filing with the FDA, because it is another positive step towards implementing our business plan and could possibly lead to future testing of cancer treatment medications for canines," stated Gary Berthold, President of PharmaCom BioVet, Inc. PharmaCom BioVet, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009